Intranasal anti-convulsive compositions and methods
US8507468B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Oct 2, 2008 |
| Grant date | Aug 13, 2013 |
| Priority date | — |
| Expiry date | Feb 24, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Contemplated pharmaceutical compositions comprise a benzodiazepine anti-convulsive compound for intranasal administration in a single phase, multi-component solvent system with water content of at least 15 vol % and a benzodiazepine concentration of at least 30 mg/ml. It is noted that contrary to common expectation, the concentration of the anti-convulsive compound was increased by increasing water content in the multi-component solvent. Moreover, the anti-convulsive compound remained chemically stable and substantially completely dissolved over large periods of time. Thus, stable and highly concentrated spray formulations for intranasal administration could be prepared having sufficiently high concentrations of the anti-convulsive compounds that now allow single spray administration to achieve clinically relevant dosages.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.